Mark J Levis


1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Mark J Levis is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Mutation Medicine & Life Sciences
Leukemia Medicine & Life Sciences
fms-Like Tyrosine Kinase 3 Medicine & Life Sciences
4'-N-benzoylstaurosporine Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
Chemotherapy Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

Arsenic and old FLT3

Levis, M. J., Mar 28 2019, In : Blood. 133, 13, p. 1392-1393 2 p.

Research output: Contribution to journalArticle


Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction

Hambley, B. C., Norsworthy, K. J., Jasem, J., Zimmerman, J. W., Shenderov, E., Webster, J., Showel, M., Gondek, L., Dalton, W., Prince, G., Gladstone, D., Streiff, M. B., Pratz, K., Gojo, I., Ghiaur, G., Levis, M. J., Smith, B. D. & Dezern, A., Aug 1 2019, In : Leukemia Research. 83, 106174.

Research output: Contribution to journalLetter

Acute Promyelocytic Leukemia

FLT3 inhibitor maintenance after allogeneic transplantation: Is a placebo-controlled, randomized trial ethical?

for the Blood and Marrow Transplant Clinical Trials Network, Jan 1 2019, In : Journal of Clinical Oncology. 37, 19, p. 1604-1607 4 p.

Research output: Contribution to journalComment/debate

Homologous Transplantation
Randomized Controlled Trials

Midostaurin for patients with acute myeloid leukemia and FLT3 mutations

Levis, M. J., Jun 1 2019, In : Clinical advances in hematology & oncology : H&O. 17, 6, p. 323-325 3 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Cortes, J. E., Khaled, S., Martinelli, G., Perl, A. E., Ganguly, S., Russell, N., Krämer, A., Dombret, H., Hogge, D., Jonas, B. A., Leung, A. Y. H., Mehta, P., Montesinos, P., Radsak, M., Sica, S., Arunachalam, M., Holmes, M., Kobayashi, K., Namuyinga, R., Ge, N. & 3 others, Yver, A., Zhang, Y. & Levis, M. J., Jul 1 2019, In : The Lancet Oncology. 20, 7, p. 984-997 14 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Drug Therapy
Intravenous Infusions